trial

Glutamatergic Mechanisms of Psychosis and Target Engagement (SA1)

NCTId NCT04589208
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Suspended
Enrollment 35 (actual)
Sponsored by New York State Psychiatric Institute, Washington Heights Community Service
Primary completion 2027-01-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Suspended
Enrollment
35 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2021-01-01
Primary completion
2027-01-01
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Ketamine Hydrochloride

Sponsors

New York State Psychiatric Institute, Washington Heights Community ServiceLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Sites

1 total
New York, United States

Linked catalysts

1
Glutamatergic Mechanisms of Psychosis and Target Engagement (SA1) — primary completion2027-01-01

Facts & assertions

4 sourced
Enrollment
35
Phase
PHASE1,PHASE2
Primary Completion Date
2027-01-01
Status
SUSPENDED
relationships
The graph out of here
drug
Ketamine Hydrochloride
drug
lead_sponsor
New York State Psychiatric Institute, Washington Heights Community Service
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Healthy
indication
Schizophrenia
indication